4314-68-5

Usage

Uses

Used in Pharmaceutical Industry:
3-(4-METHOXY-PHENYL)-2-PHENYL-PROPIONIC ACID is used as an analgesic and anti-inflammatory agent for the treatment of conditions such as arthritis, menstrual cramps, and musculoskeletal injuries. It is valued for its effectiveness in reducing inflammation and pain, making it a common choice for medical management of these ailments.
As a Prescription and Over-the-Counter Medication:
3-(4-METHOXY-PHENYL)-2-PHENYL-PROPIONIC ACID is utilized in both prescription and over-the-counter forms, typically administered orally in the form of tablets or capsules. This accessibility allows for a wide range of patients to benefit from its therapeutic properties.
For Alleviating Side Effects:
While generally well-tolerated, 3-(4-METHOXY-PHENYL)-2-PHENYL-PROPIONIC ACID may cause side effects like stomach irritation, headache, and dizziness in some individuals. Its use in medical treatment involves balancing the benefits of pain relief and inflammation reduction with potential side effects, ensuring patient safety and comfort.

InChI:InChI=1/C16H16O3/c1-19-14-9-7-12(8-10-14)11-15(16(17)18)13-5-3-2-4-6-13/h2-10,15H,11H2,1H3,(H,17,18)/p-1/t15-/m1/s1

Upstream product

• 1262329-30-5 C₁₆H₁₃ClO₃ 
• 2177-74-4 (2E)-2-(4-chlorophenyl)-3-(4-methoxyphenyl)prop-2-enoic acid 
• 5448-41-9 methyl 3-(4'-methoxyphenyl)-2-phenylpropanoate 
• 2746-25-0 p-Methoxybenzyl bromide 
• 101-41-7 benzeneacetic acid methyl ester 
• 6968-77-0 2-phenyl-3-p-methoxyphenylacrylic acid 
• 103-82-2 phenylacetic acid 
• 824-94-2 p-methoxybenzyl chloride 
• 6968-77-0 3-(4-methoxyphenyl)-2-phenylacrylic acid 

Downstream Products

• 19842-21-8 3-(4-methoxyphenyl)-2-phenylpropanoyl chloride 
• 106319-23-7 (2R)-3-(4-methoxyphenyl)-2-phenylpropanoic acid 
• 577-91-3 3-(4-hydroxy-3,5-diiodo-phenyl)-2-phenyl-propionic acid 
• 109250-59-1 ethyl 3-(4-methoxyphenyl)-2-phenylpropanoate 
• 875231-52-0 3-(4-methoxyphenyl)-2-methyl-2-phenylpropanoic acid 
• 1538615-09-6 ethyl 3-(4-methoxyphenyl)-2-methyl-2-phenylpropanoate 
• 116132-52-6 (1R,3r,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 3-(4-methoxyphenyl)-2-phenylpropanoate 
• 5189-39-9 2-Phenyl-3--6-methoxyinden-3-¹⁴C 
• 57151-38-9 1-amino-2-(p-methoxyphenyl)-1-phenylethane 
• 80654-78-0 1-{6,7-Dimethoxy-1-[2-(4-methoxy-phenyl)-1-phenyl-ethyl]-3,4-dihydro-1H-isoquinolin-2-yl}-ethanone 
• 80654-75-7 2-Ethyl-6,7-dimethoxy-1-[2-(4-methoxy-phenyl)-1-phenyl-ethyl]-1,2,3,4-tetrahydro-isoquinoline 
• 80654-63-3 N-[2-(3,4-Dimethoxy-phenyl)-ethyl]-3-(4-methoxy-phenyl)-2-phenyl-propionamide 
• 80654-71-3 6,7-Dimethoxy-1-[2-(4-methoxy-phenyl)-1-phenyl-ethyl]-1,2,3,4-tetrahydro-isoquinoline 
• 80654-67-7 6,7-Dimethoxy-1-[2-(4-methoxy-phenyl)-1-phenyl-ethyl]-3,4-dihydro-isoquinoline 

Relevant academic research and scientific papers

AZABICYCLO AND DIAZEPINE DERIVATIVES FOR TREATING OCULAR DISORDERS

The present invention provides in one aspect azabicycio and diazepine derivatives useful as modulators of muscarinic receptors. In another aspect, the present invention provides pharmaceutical compositions for treating ocular diseases, the compositions comprising at least one muscarinic receptor modulator. Formulae (I) & (II):

GUANIDINE DERIVATIVES AS TRPC MODULATORS

The present invention is directed to guanidine derivatives as inhibitors of transient receptor potential canonical channels (TRPC channels), in particular TRPC3 and/or TRPC6 and/or TRPC7 activity, more particularly TRPC6 activity. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders mediated by TRPC channels (Formula (I))

Reactions of chlorine substituted (E)-2,3-diphenylpropenoic acids over cinchonidine-modified Pd: Enantioselective hydrogenation versus hydrodechlorination

The effect of the chlorine position on the C-Cl bond hydrogenolysis and the enantioselective hydrogenation of Cl substituted (E)-2,3-diphenylpropenoic acid derivatives has been studied over cinchonidine-modified Pd/Al2O 3. In contrast to the fast hydrodechlorination of the β-phenyl-para-Cl substituted acids the Cl on the α-phenyl ring was barely hydrogenolized. These observations were interpreted by the different arrangements of the two phenyl rings on the surface, with the α- and β-phenyl rings adsorbed tilted and parallel, respectively. The results confirmed the beneficial effect of the α-phenyl-ortho-substituents on the chiral discrimination, thus the 2,3-diphenylpropionic acids substituted by Cl on the α-phenyl ring could be prepared in good yields and optical purities. The conclusions were used for the rational design of an acid, i.e. (E)-2-(2-methoxyphenyl)-3-(3,4-difluorophenyl)propenoic acid, which afforded the best optical purity (ee up to 95% at 295 K) described until now in this heterogeneous system.

NEW COMPOUNDS, WHICH ARE POTENT INHIBITORS OF NA/CA EXCHANGE MECHANISM AND ARE USEFUL IN THE TREATMENT OF ARRHYTHMIAS

Therapeutically active compounds of formula (I): wherein X is -O-, -CH2- or -C(O)-; Z is -CHR9- or valence bond; Y is -CH2-, -C(O)-, CH(OR10)-, -CH(NR11R12 )-, -O-, -S-, -S(O)- or -S(O2)-, provided that in case Z is a valence bond, Y is not C(O); the dashed line represents an optional double bond in which case Z is -CR9- and Y is -CH-, C(OR10)- or -C(NR11R12 )-; R1 is -(CH2)nNR4R7 or one of the following groups:n is 1 - 4; R2 and R3 are independently H, lower alkyl, lower alkoxy, -NO2, halogen, -CF3, -OH, -NHR8 or -COOH; R4 and R7 are independently H, lower alkyl or lower hydroxyalkyl; R5 is H, lower alkoxy, -CF3, -NH2 or -CN; R6 is -NO2 , -NR14R19, -CF3 or R8 and R16 are independently H or acyl; R9 is H or lower alkyl; R10 is H, alkylsulfonyl or acyl; R11 and R12 are independently H, lower alkyl or acyl; R13 and R18 are independently H or -OR20; R14 and R19 are independently H, acyl, alkylsulfonyl, C(S)NHR17 or C(O)NHR17; R15 is H or NH2; R17 is H or lower alkyl; R20 is H or acyl; and pharmaceutically acceptable salts and esters thereof are disclosed. The compounds are potent inhibitors of Na/Ca exchange mechanism.

IMIDAZOLE COMPOUNDS AS Alpha2-ADRENOCEPTORS ANTAGONISTS

An imidazole derivative of formula (I) or a pharmaceutically acceptable salt or derivative thereof. The compounds of formula (I) exhibit affinity for alpha2 adrenoceptors.

PYRIDINE DERIVATIVES USEFUL FOR INHIBITING SODIUM/CALCIUM EXCHANGE SYSTEM

Therapeutically active compounds of formula (I) or (II) wherein X is -O-, -CH2- or -C(O)-; Z is -CHR12- or a valence bond; Y is -CH2-, -C(O)-, CH(OR13)-, -O-, -S-; provided that in case Z is a valence bond, Y is not C(O); the dashed line representing an optional double bond in which case Z is -CR12- -and Y is -CH2-, -C(O)- or -CH(OR10)- (in formula II) or -CH- (in formula I); R2 and R3 are independently H, lower alkyl, lower alkoxy, -NO2, halogen, -CF3, -OH, benzyloxy or a group of formula (IIIa). R1 is H, CN, halogen, -CONH2, -COOR15, CH2NR15R18, NHC(O)R5, NHCH2R5, NHR20, NR21R22, NHC(NH)NHCH3 or, in case the compound is of formula (II) wherein the optional double bond exists or in case R2 or R3 is benzyloxy or a group of formula (IIIa) or in case the pyridine ring of formula (I) or (II) is attached to the oxygen atom in 3-, 4- or 5-position, R1 can also be -NO2 or NR16R17; R4 is H, -NO2, CN, halogen, -CONH2, -COOR15, -CH2NR15R18, -NR16R17, NHC(O)R5 or -NHC(NH)NHCH3; R5 is alkyl substituted with 1-3 substituents selected from the group consisting of halogen, amino and hydroxy, or carboxyalkyl, in which the alkyl portion is optionally substituted with 1-3 substituents selected from the group consisting of halogen, amino and hydroxyl, -CHR6NR,R8 or one of the following groups: formula (IVa), (IVb), (IVc), (IVd), (IVe), and pharmaceutically acceptable salts and esters thereof. The compounds are potent inhibitors of Na+/Ca2+ exchange mechanism.

Imidazole derivatives

An imidazole derivative of formula (I) or a pharmaceutically acceptable salt or derivative thereof. The compounds of formula I exhibit affinity for alpha2 adrenoceptors.